By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile 

Phone: Fax:


Company News Approves Celltrion (068270.KQ)’s INFLECTRA, the First Cheaper Version of Johnson & Johnson (JNJ) Blockbuster Remicade 4/6/2016 6:19:31 AM Head Accused of Conspiring to Suppress Information About Harmful Effects of Johnson & Johnson (JNJ) Antibiotic 2/9/2016 6:59:56 AM Grants Orphan Drug Status to Eisai Inc. (ESALF.PK)'s Lenvatinib 2/14/2013 8:56:14 AM Rejects United Therapeutics Corporation (UTHR) Lung Drug 10/24/2012 7:48:35 AM : Salix Pharmaceuticals, Ltd. (SLXP) Supports Proposed Clinical Trial Design to Evaluate Repeat Treatment Cycles of XIFAXAN® for Irritable Bowel Syndrome with Diarrhea 11/17/2011 6:21:16 AM Grants Fluke Biomedical 510(k) Clearance for New ProSim(TM) Vital Signs Simulators 9/9/2011 7:14:59 AM Approves Addition of Sustained Overall Survival Benefit to Label for Takeda (TKPYY)'s (JOBS) VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 1/5/2010 6:50:41 AM to Webcast via TalkPoint the FDA Review of Bayer Corporation (BAY) and Johnson & Johnson (JNJ) Anti-Clot Drug Rivaroxaban on March 19th 3/11/2009 11:49:55 AM
FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS(TM) (raltegravir), Merck & Co., Inc. (MRK)'s Investigational Oral Integrase Inhibitor, for Treatment of HIV 9/5/2007 2:53:45 PM
Columbia Laboratories, Inc. (CBRX) Comments On FDA Reproductive Drugs Advisory Committee Recommendation On 17-OHPC; PROCHIEVE 8% Currently In Phase III Clinical Trial For Prevention Of Recurrent Preterm Birth 8/30/2006 12:17:20 PM